Ibrutinib Monotherapy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma: A Retrospective Single Center Experience from India

Conclusions: This analysis from a single-center showed the clinical outcomes of ibrutinib monotherapy over a relatively short treatment duration, in Indian patients. Ibrutinib may serve as a bridge to transplant in relapsed refractory CLL and MCL as reported in two patients here. Clinical outcomes reported here from a single center are similar to that reported in pivotal trials of ibrutinib and from named patient program of ibrutinib in India.DisclosuresAgarwal: Rajiv Gandhi Cancer Institute and Research Center: Employment. Gurha: Medical Affairs, Janssen, Johnson and Johnson Pvt ltd, India: Employment. Shah: Medical Affairs, Janssen, Johnson and Johnson Pvt ltd, India: Employment. Narang: Medical Affairs, Janssen, Johnson and Johnson Pvt ltd, India: Employment.

Source: Blood - November 21, 2018 Category: Hematology Authors: Ahmed, R., Bhurani, D., Agarwal, N., Kapoor, J., Gurha, N., Shah, M., Narang, P. Tags: 642. CLL: Therapy, excluding Transplantation Source Type: research